Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
Cidara Therapeutics, Inc. (CDTX)
Last cidara therapeutics, inc. earnings: 3/4 05:55 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cidara.com
Company Research
Source: GlobeNewswire
Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical development and CMC costs over the next three years and an additional approximately $61 million in forecasted obligations through the patent life of rezafungin Cidara to further focus on advancing Cloudbreak development programs, including a planned IND filing for its lead oncology candidate, CBO421, as well as advancing other pipeline assets SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it has entered into an asset purchase agreement with its current partner, Mundipharma*, for the divestiture of rezafungin. Mundipharma currently has commercial rights to rezafungin outside t
Show less
Read more
Impact Snapshot
Event Time:
CDTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDTX alerts
High impacting Cidara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CDTX
News
- Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
- Cidara Therapeutics, Inc. (CDTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
- Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform [Seeking Alpha]Seeking Alpha
- Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 [Yahoo! Finance]Yahoo! Finance
- Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024GlobeNewswire
CDTX
Earnings
- 11/2/23 - Beat
CDTX
Sec Filings
- 5/3/24 - Form 8-K
- 4/30/24 - Form 4
- 4/30/24 - Form 3
- CDTX's page on the SEC website